Abstract Details

Title Use of CT Head in the Pediatric Emergency Room in the Evaluation of Children with First Afebrile Seizure

Topic Child Neurology and Developmental Neurology

Presentation(s) P3 - (-)

Poster/Presentation
Number 215

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Aravindhan Veerapandiyan, MD (Arkansas Childrens Hospital/UAMS) PRESENTER	Dr. Veerapandiyan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen, Novartis,Edgewise Therapeutics, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Inc., UCB Pharma, Catalyst, Entrada, Lupin, Percheron, ITF. Dr. Veerapandiyan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MedLink Neurology. Dr. Veerapandiyan has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Muscle and Nerve. The institution of Dr. Veerapandiyan has received research support from AMO Pharma, Capricor Therapeutics, Edgewise Therapeutics, FibroGen, Muscular Dystrophy Association, Novartis, Parent Project Muscular Dystrophy, Pfizer, RegenxBio, SolodBio and Sarepta Therapeutics. Dr. Veerapandiyan has received personal compensation in the range of $5,000-$9,999 for serving as a MD with PPMD, MDA.
	No disclosure on file
	No disclosure on file
Devorah Segal, MD, PhD (NYU Langone)	Dr. Segal has nothing to disclose.
Xue Ming, MD (Dept of Neurosciences)	Dr. Ming has nothing to disclose.

��ɫ����